is the fda taking tirzepatide off the market Drug Recalls and Warnings: Illegal GLP-1 Sales and Misleading Marketing by Novo Nordisk and Eli Lilly May 18, 2026: FDA warns

However, for sustained weight loss, Ozempic should not be used in isolation

Clinical report: a small retrospective knee-pain series used telephone follow-up and had no control group

Unlike the titration phasewhere your dose climbs every four weeksthe maintenance phase holds steady because further increases no longer improve results meaningfully

Other medications in the GLP-1 class include liraglutide and tirzepatide (a dual-pathway medication that works on both GLP-1 and GIP receptors)

Unrealistic Claims or Guarantees Be skeptical of providers claiming: FDA-approved compounded semaglutide (compounded products arent FDA-approved) Guaranteed specific weight loss amounts No side effects Superior effectiveness to brand-name versions Pharmaceutical grade without proper documentation Pressure Tactics Legitimate providers never: Rush you into starting treatment Pressure you to commit to long-term contracts immediately Use fear tactics about brand-name shortages Discourage you from consulting other providers Create artificial urgency with limited supply claims Poor Communication or Customer Service Warning signs include: Inability to reach a human representative No licensed pharmacist available for questions Delayed or no responses to medical concerns Generic email responses that dont address specific questions No clear emergency contact procedures Lack of Follow-Up Care Safe semaglutide use requires ongoing monitoring

Both Mounjaro and Ozempic influence metabolic systems in various ways